These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 212812)

  • 1. [Causes of failure in neutralization, recovery and social rehabilitation of chronic eliminators of Koch bacilli treated with rifampin and ethambutol].
    Barbu Z; Alexa M; Josefovics F
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1978; 27(3):153-9. PubMed ID: 212812
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dynamics of rifampicin and ethambutol resistance of strains of Koch bacilli isolated from patients with pulmonary tuberculosis 1973-1981].
    Ionescu C; Timoşca S; Petreanu V; Petreanu C; Georgescu M; Martinescu T
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1982; 31(4):315-20. PubMed ID: 6304845
    [No Abstract]   [Full Text] [Related]  

  • 3. [Activity of the second-line preparations, ethambutol and rifampin, in experimental tuberculosis caused by Mycobacterium tuberculosis highly resistant to basic tuberculostatics].
    Golyshevskaia VI; El'shanskaia MP
    Probl Tuberk; 1973; 51(12):60-4. PubMed ID: 4205666
    [No Abstract]   [Full Text] [Related]  

  • 4. [Proceedings: Preliminary results of a 2-phase therapy with rifampicin, ethambutol and a third drug in chronic polyresistant tuberculoses].
    Neumeyer D; Anschel R; Eule H; Fichtner K; Ganguin HG; Pickroth G
    Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):135-8. PubMed ID: 4491710
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term results of treatment with rifampicin and ethambutol in hyperchronic pulmonary tuberculosis with polyresistant bacilli].
    Anastasatu C; Sibila S
    Ftiziologia; 1973; 22(5):477-84. PubMed ID: 4751363
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bacteriologic negation and anatomic development in pulmonary specimens after rifampicin treatment of less than 10 months (10 cases)].
    Constans P; Parrot R; Coury C
    Rev Tuberc Pneumol (Paris); 1970 Jun; 34(4):511-8. PubMed ID: 4994883
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic drug-resistant pulmonary tuberculosis with rifampin and ethambutol.
    Jeanes CW; Jessamine AG; Eidus L
    Can Med Assoc J; 1972 Apr; 106(8):884-8. PubMed ID: 4623743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Survival of tuberculous bacilli in combined treatments including rifampicin].
    Kreis B; Pretet S
    Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-course treatment regimens for patients with tuberculosis.
    Dutt AK; Stead WW
    Arch Intern Med; 1980 Jun; 140(6):827-9. PubMed ID: 6770770
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifampicin and ethambutol in the treatment of drug resistant and far advanced pulmonary tuberculosis (with a note on capreomycin).
    Pines A; Raafat H; Siddiqui GM
    J Ir Med Assoc; 1970 Mar; 63(393):82-5. PubMed ID: 4984340
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical significance of drug resistance of tuberculosis mycobacteria and L-forms].
    Golanov VS; Bogdalova VE; Andreev LP; Losin EI; Ushakova AG; Meshcheriakov VG; Bondin SV
    Probl Tuberk; 1991; (12):27-8. PubMed ID: 1803368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bacteriostatic activity of the blood in pulmonary tuberculosis and its clinical significance].
    Alekseenko AM
    Probl Tuberk; 1979 Jan; (1):33-7. PubMed ID: 105352
    [No Abstract]   [Full Text] [Related]  

  • 13. [Changes in the bacteriologic findings in patients treated with rifomycin, alone or associated with other drugs].
    Delli Veneri F; Centrella G; Stefanelli R
    Arch Tisiol Mal Appar Respir; 1968 May; 23(5):387-98. PubMed ID: 4979475
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of rifampicin in the treatment of tuberculosis and nonspecific inflammatory lung diseases].
    Rudoĭ NM; Zankisova IG; Eĭsaev BA
    Antibiotiki; 1975 Oct; 20(10):945-8. PubMed ID: 813565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of isoniazid-resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin: a co-operative study in England and Wales.
    Andrews RH; Jenkins PA; Marks J; Pines A; Selkon JB; Somner AR
    Tubercle; 1974 Jun; 55(2):105-13. PubMed ID: 4143450
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rifampicin combined with ethambutol and other antitubercular agents in the treatment of patients with chronic pulmonary tuberculosis. Early results. II. Analysis of causes of treatment interruption].
    Masztalerz J
    Pneumonol Pol; 1976 Feb; 44(2):153-61. PubMed ID: 940788
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mechanism of the side effects of rifadin and ethambutol].
    Firsova LP; Liuboshenko LA
    Probl Tuberk; 1975; (12):42-5. PubMed ID: 1221423
    [No Abstract]   [Full Text] [Related]  

  • 18. [Daily and intermittent regimens using ethambutol and rifampicin in the treatment of unresponsive cases. (Evaluation after 1 year.) II. Side effects].
    Girling DJ
    Bull Int Union Tuberc; 1974; 49(1):451-5. PubMed ID: 4619567
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifampin plus isoniazid in initial therapy of pulmonary tuberculosis and rifampin and ethambutol in retreatment cases.
    Lees AW; Allan GW; Smith J; Tyrell WF; Fallon RJ
    Chest; 1972 Jun; 61(6):579-82. PubMed ID: 4260668
    [No Abstract]   [Full Text] [Related]  

  • 20. [Place of bacteriological examination in the treatment of tuberculosis].
    Gyselen A
    Acta Tuberc Pneumol Belg; 1972; 63(4):405-8. PubMed ID: 4206438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.